David L. Cooper, PHD, MD

CEO

As the Founder and Chief Executive Officer, Dr. Cooper is a well-known physician/scientist with 35+ years of professional experience. Dr. Cooper’s clinical effort, basic medical science research and influential professional society leadership is highly regarded in both academic and commercial circles. As the founder and first president of the Association for Molecular Pathology (AMP), he contributed to the professional development and recognition of the subdiscipline of Molecular Pathology and Genetics. His subsequent executive work as CSO Quest Diagnostics and the Nichols Institute further promoted commercialization of molecular diagnosis globally. His management experience spans C-level executive positions from biotech, diagnostic and pharmaceutical start-ups to Fortune 500 companies. His investigator-initiated work has been recognized with multiple funded awards from the NIH, DOD, ACS and SBIR with 100+ scientific manuscripts published. Honors include the Litchfield Lectureship, Oxford University for clinical and research leadership in Molecular Medicine. Most recently Dr. Cooper has devoted his efforts to a better understanding of phytocannabinoids and the endocannabinoid system’s role in health and disease. Designing empiric data generating safe, efficacious and cost-efficient IRB approved clinical studies is the focus of his ongoing activities as CEO of PhytoDental Solutions, Inc.